Drugs / PURETHAL Mites 50,000 AUeq/ml
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06920771 Comparator | Sep 2024 → Apr 2026 overdue | house allergic alveolitis, perennial allergic rhinitis | HAL Allergy | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PURETHAL Mites 50,000 AUeq/ml | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06920771 ↗ |
| Known as | PM Mixture | “PM Mixture is a suspension of chemically modified extract from the house dust mites Dermatophagoides pteronyssinus (D. pter) and Dermatophagoides farinae (D. far), adsorbed to...” NCT06920771 ↗ |
| Modality | Other / unclassified | “PM Mixture is a suspension of chemically modified extract from the house dust mites Dermatophagoides pteronyssinus (D. pter) and Dermatophagoides farinae (D. far), adsorbed to...” NCT06920771 ↗ |
| Route | Subcutaneous | “will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached” NCT06920771 ↗ |